India’s $10 billion pipeline of generic cures will keep rolling—for nowByTim FernholzPublishedApril 1, 2013
Novartis wanted to pay an exec $78 million to keep secrets that don’t existByGwynn GuilfordPublishedFebruary 19, 2013
Teva, maker of generic and brand-name drugs, feels the pressure of both industriesByQZPublishedFebruary 7, 2013
